All In Biotech

NDA 217581 · Pf Prism Cv

Xalkori

Crizotinib · Oral · Kinase Inhibitor

Orphan

Last checked: Nov 19, 2026Latest source record: Sep 7, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2023

Sep 7, 2023

Approved uses

1

Original approval plus efficacy supplements

Registered trials

148

25 Phase 3, 14 recruiting

FAERS reports

12,739

9,350 serious, 3,853 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Oct 29, 2026.

XALKORI is a kinase inhibitor indicated for the treatment of • adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK) or ROS1-positive as detected by an FDA-approved test. ( 1.1 , 2.1 ) • pediatric patients 1 year of age and older and young adults with relapsed or refractory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive. ( 1.2 , 2.3 ) o Limitations of Use: The safety and efficacy of XALKORI have not been established in older adults with relapsed or refractory, systemic ALK-positive ALCL. • adult and pediatric patients 1 year of age and older with unresectable, recurrent, or refractory inflammatory myofibroblastic tumor (IMT) that is ALK-positive. ( 1.3 , 2.3 ) 1.1 ALK- or ROS1-Positive Metastatic Non-Small Cell Lung Cancer XALKORI is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK) or ROS1-positive as detected by an FDA-approved test [see Dosage and Administration (2.1) ] . 1.2 Relapsed or Refractory, Systemic ALK-Positive Anaplastic Large Cell Lymphoma XALKORI is indicated for the treatment of pediatric patients 1 year of age and older and young adults with relapsed or refractory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive . Limitations of Use : The safety and efficacy of XALKORI have not been established in older adults with relapsed or refractory, systemic ALK-positive ALCL. 1.3 Unresectable, Recurrent, or Refractory ALK-Positive Inflammatory Myofibroblastic Tumor XALKORI is indicated for the treatment of adult and pediatric patients 1 year of age and older with unresectable, recurrent, or refractory inflammatory myofibroblastic tumor (IMT) that is ALK-positive.

Mechanism: Crizotinib is an inhibitor of receptor tyrosine kinases including ALK, Hepatocyte Growth Factor Receptor (HGFR, c-Met), ROS1 (c-ros), and Recepteur d'Origine Nantais (RON). Translocations can affect the ALK gene resulting in the expression of oncogenic fusion proteins. The formation of ALK fusion proteins results in activation and dysregulation of the gene's expression and signaling which can contribute to increased cell proliferation and survival in tumors expressing these proteins. Crizotinib demonstrated concentration-dependent inhibition of ALK, ROS1, and c-Met phosphorylation in...

Therapeutic areas: Oncology

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

3 products under this application
  • XALKORI · CRIZOTINIB 50MG · CAPSULE, PELLETS, ORAL · Prescription
  • XALKORI · CRIZOTINIB 150MG · CAPSULE, PELLETS, ORAL · Prescription
  • XALKORI · CRIZOTINIB 20MG · CAPSULE, PELLETS, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Crizotinib" as an intervention, any sponsor and status, largest first.

All 148 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • death2,379
  • disease progression1,217
  • nausea1,124
  • neoplasm progression1,110
  • diarrhoea849
  • vomiting799
  • fatigue557
  • off label use474
  • oedema peripheral449
  • constipation442
  • dyspnoea432
  • lung neoplasm malignant420

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2011109
2012774
20131,097
20141,298
20151,195
20161,140
20171,012
20181,024
20191,074
2020813
2021661
2022660
2023629
2024587
2025407
2026259

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Xalkori (Crizotinib)

2024 spending

$58.9M

Beneficiaries

406

2,952 claims

Per beneficiary

$145,013

$365.28 per unit

View as table
YearSpending
2020$62,640,524
2021$53,046,547
2022$58,588,555
2023$52,137,023
2024$58,875,150

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 268 on PubMed

Sponsor: Pf Prism Cv

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.